DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Heart Failure | Preserved Ejection Fraction | Treatment Algorithms: Claims Data Analysis | US | 2023
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and understanding of the disease’s pathophysiology has improved…
Heart Failure | Reduced Ejection Fraction | Treatment Algorithms: Claims Data Analysis | US | 2023
Drug treatment of chronic heart failure with reduced ejection fraction (HFrEF) is well established, with a wealth of supporting evidence from clinical trials. ACE inhibitors or ARBs, beta blockers…
Chronic Heart Failure | Reduced Ejection Fraction | Treatment Algorithms | Claims Data Analysis | US | 2022
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…
Chronic Heart Failure | Preserved Ejection Fraction | Treatment Algorithms | Claims Data Analysis | US | 2022
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…
Chronic Heart Failure | Preserved Ejection Fraction | Treatment Algorithms | Claims Data Analysis | US | 2021
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…
Chronic Heart Failure | Preserved Ejection Fraction | Treatment Algorithms | Claims Data Analysis | US | 2020
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…
